Foundayo, an oral medication manufactured by Eli Lilly, became available in UK pharmacies earlier this week following regulatory approval by the Medicines and Healthcare products Regulatory Agency. The drug, containing the active ingredient orforglipron, represents the second weight-loss pill to receive authorization in the UK, with the nation becoming the first in Europe to approve this particular formulation.
The medication is indicated for individuals with a body mass index of 30 or above, as well as those with a BMI between 27 and 30 who have at least one weight-related medical condition. It is also licensed to help improve blood sugar control in patients with type 2 diabetes that is not adequately managed through other means. The treatment comes in tablet form taken once daily without dietary or fluid restrictions.
Currently, Foundayo is being distributed through private prescription channels. Eli Lilly stated it is collaborating with the National Institute for Health and Care Excellence to pursue potential inclusion in NHS treatment options in England. Khalil Asmar, vice-president of cardiometabolic health at Lilly Northern Europe, noted that the availability provides additional options for eligible patients alongside injectable alternatives already on the market.
Pharmacy representatives indicated the launch addresses a significant gap for patients unable or unwilling to use injectable formulations. However, officials have raised concerns about the proliferation of counterfeit and unlicensed versions of weight-loss medications. The MHRA previously seized £250,000 worth of unlicensed weight-loss products from a facility, and Eli Lilly has initiated legal action against suppliers allegedly involved in unauthorized drug markets. Patients are being advised to obtain treatments exclusively through regulated pharmacy channels.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI